Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC“Continuation therapy with atezolizumab (Tecentriq) following progression on first-line chemo-immunotherapy produced promising efficacy and manageable safety in a small cohort of patients with...
For cancer patients, oncologists often have the final word“For terminally ill cancer patients, the final days of life are immensely personal, having the choice to continue cancer treatments, or to stop treatments and prioritize a more comfortable passing. What a...
More News and Updates